Spruce Biosciences, Inc. (SPRB)
Largest Insider Buys in Sector
SPRB Stock Price History Chart
SPRB Stock Performance
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for …
Insider Activity of Spruce Biosciences, Inc.
Over the last 12 months, insiders at Spruce Biosciences, Inc. have bought $0 and sold $3.41M worth of Spruce Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Spruce Biosciences, Inc. have bought $19.12M and sold $5.12M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,208,000 shares for transaction amount of $7M was made by Novo Holdings A/S (10 percent owner) on 2023‑02‑16.
List of Insider Buy and Sell Transactions, Spruce Biosciences, Inc.
| 2024-03-21 | Sale | 10 percent owner | 465,021 1.1289% | $0.75 | $350,951 | -27.33% | ||
| 2024-03-20 | Sale | 10 percent owner | 359,979 0.8709% | $0.73 | $264,081 | -26.45% | ||
| 2024-03-19 | Sale | 10 percent owner | 593,000 1.4693% | $0.76 | $447,715 | -26.79% | ||
| 2024-03-18 | Sale | 10 percent owner | 842,020 2.0939% | $0.77 | $647,008 | -27.77% | ||
| 2024-03-14 | Sale | 10 percent owner | 1.91M 0.8272% | $0.89 | $1.7M | -34.27% | ||
| 2023-02-16 | 10 percent owner | 2.21M 0.0087% | $3.17 | $7M | -11.16% | |||
| 2023-02-16 | director | 630,400 0.0025% | $3.17 | $2M | -11.16% | |||
| 2021-05-20 | Sale | director | 334 0.0014% | $15.29 | $5,107 | -71.33% | ||
| 2021-05-19 | Sale | 10 percent owner | 475,000 1.8365% | $13.90 | $6.6M | -71.54% | ||
| 2021-04-30 | Sale | director | 14,045 0.06% | $16.14 | $226,664 | -71.70% | ||
| 2020-10-14 | 10 percent owner | 250,000 0.9752% | $15.00 | $3.75M | -10.92% | |||
| 2020-10-14 | 250,000 0.9752% | $15.00 | $3.75M | -10.92% | ||||
| 2020-10-14 | director | 250,000 0.9752% | $15.00 | $3.75M | -10.92% | |||
| 2020-10-14 | 10 percent owner | 250,000 0.9752% | $15.00 | $3.75M | -10.92% | |||
| 2020-10-14 | 250,000 0.9752% | $15.00 | $3.75M | -10.92% | ||||
| 2020-10-14 | director | 250,000 0.9752% | $15.00 | $3.75M | -10.92% | |||
| 2020-10-14 | director | 200,000 0.7802% | $15.00 | $3M | -10.92% | |||
| 2020-10-14 | director | 250,000 0.9752% | $15.00 | $3.75M | -10.92% |
Insider Historical Profitability
| Novo Holdings A/S | 10 percent owner | 2550000 6.1739% | $0.48 | 2 | 6 | <0.0001% |
| Omega Fund VI, L.P. | 2161022 5.2322% | $0.48 | 1 | 0 | <0.0001% | |
| Chaya Moghrabi Dina | director | 2161022 5.2322% | $0.48 | 1 | 0 | <0.0001% |
| RiverVest Venture Fund III, L.P. | 10 percent owner | 2148281 5.2013% | $0.48 | 1 | 0 | <0.0001% |
| HealthCap VIII, L.P. | 2033621 4.9237% | $0.48 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| RiverVest | $2.31M | 7.14 | 2.94M | 0% | +$0 | 28.35 | |
| The Carlyle Group | $2.28M | 7.04 | 2.9M | 0% | +$0 | 0.1 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $2.05M | 6.34 | 2.61M | 0% | +$0 | 0.05 | |
| Aisling Capital Management LP | $947,532.00 | 2.93 | 1.21M | 0% | +$0 | 0.32 | |
| Altium Capital Management Lp | $903,785.00 | 2.79 | 1.15M | New | +$903,785.00 | 0.11 |